Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 122.50 27,947 01:00:00
Bid Price Offer Price High Price Low Price Open Price
115.00 130.00 122.50 122.50 122.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 6.07 -13.86 -35.90 39
Last Trade Time Trade Type Trade Size Trade Price Currency
15:23:25 O 400 117.20 GBX

Reneuron (RENE) Latest News (1)

More Reneuron News
Reneuron Takeover Rumours

Reneuron (RENE) Discussions and Chat

Reneuron (RENE) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Reneuron trades in real-time

Reneuron (RENE) Top Chat Posts

Reneuron Daily Update: Reneuron Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker RENE. The last closing price for Reneuron was 122.50p.
Reneuron Group Plc has a 4 week average price of 112.50p and a 12 week average price of 112.50p.
The 1 year high share price is 297.50p while the 1 year low share price is currently 73p.
There are currently 31,833,770 shares in issue and the average daily traded volume is 46,687 shares. The market capitalisation of Reneuron Group Plc is £38,996,368.25.
onceaday: Let's hope they start the ph2a extension study soon. If indeed the company needs to raise.funds then they will be doing all they can to get the share price higher. I suspect they will release an ipdate within one.month of treating a subset of the planned 9 patients if results are "material". Possibly within 90 days.
supernumerary: They started some action with the exosomes back at the beginning of 2019: but it seems to have gone nowhere. No use having assets sitting on the shelf gathering dust - if they can't be used they should be sold for whatever they can get, with a payback on future royalties.
dickbush: Re Woodford Equity Income Fund. "BlackRock has been tasked with selling down the bulk of the fund's quoted stocks while PJT Park Hill will offload unquoted companies and selected listed but hard-to-trade small companies, ahead of a first distribution to investors expected in January." Rene was over £3 when Woodford's problems became public. Even taking into account the poorer than expected results from the RP update, we should see a much higher price once Woodford's Funds' holding is sold. The problem for the share price is getting from here to there. I hope to see a resolution by end-January 2020. I don't expect the results in ten days time to make much difference unless they have news on a Fosun-like deal. It's about time the guy who was hired to make such deals started to earn his salary.
dickbush: Me, too, xow98. I didn't read the detail. Both the RNS at 15.21 and at 17.36 yesterday say "No trading in the stock-voting control interest over stock transferred." A pretty unusual RNS. Apologies to all for my previous speculation. So, the whole 33% is still overhanging RENE's share price, but now it is the hands of willing sellers who probably want to get it done asap, and have less incentive than Woodford to try hard to get it done at as high a price as possible. But they will get it done in the next couple of months. It doesn't make a difference to long term investors, but RENE's Board must be very frustrated.
s1zematters: Size hates banging his own chest but did not see anyone else posting warnings of this share price action to 190 then 140p when at 260p, so i felt obliged to help the less fortunate. I am sure you will all now be queuing to thank me, please skip rats, don't make me blush!! (i am bowing as you read this) ----------------------------------------------------------------------- s1zematters - 02 Oct 2019 - 15:22:42 - 7193 of 7337 business - RENE Like moi stated, 190p looks certain very short term; and then once that gives away it could be 120p-140p within a few weeks. This story here is unfurling, and the highly inflated share price has not yet caught up with the uncertainty that the rns (spun in a way to avoid plain English) has delivered. aimho
s1zematters: Dearest Peggy, Please do not concern yourself with the rush and push of the daily share price, for if you really were a genuine investor such falls wouldn't concern you; as no doubt the treatment will eventually come good and the share price will 10 bag? The only people that should be worried are the red/black aim gamblers skip rats caught trying to make an uneducated punt and a quick buck, and now hold the classic busted flush . They are the ones who seem to cry about the price action on such falls, hey Peggy? ----------------------------------------------------------------------------------- EGGY6198 - 03 Oct 2019 - 13:04:30 - 7262 of 7274 business - RENE If woodford isnt selling this is just fixed. How low can they take it is the only question before the conference --------------------------------------------------------------------------------- EGGY6198 - 02 Oct 2019 - 15:49:22 - 7196 of 7274 RENE Clearly this has been shorted at this point cant all want in below 2 quid. Its hard to understand this drop other than BS and shorters -------------------------------------------------------------------------------- EGGY6198 - 02 Oct 2019 - 15:38:58 - 7194 of 7275 RENE I really wish derampers would f off why would it go 120? The mcap is alreadynpeanuts and the product works.
s1zematters: supernumerary The previous data has built up a certain amount of expectation. The company recently talked about NHS treatment in a presentation pushed in a you-tube video pumped on this very thread! If the share price yesterday had an element already built in of expectation of widespread future uptake (including nhs) then today's new data questions that somewhat. That was my point!. Shares look forward in this sector by many years, some of the exuberance of the future has been depressed by that data. Moreover, future commercial returns have naturally also been questioned today by some. Temporarily ? Maybe, maybe not! I am not claiming that the treatment in this state would be offered to the NHS as you alluded, that's not only ridiculous, but the genuine "straw man" argument suggesting i was . It's a question mark of expectation of widespread future usage that in part explains the share price collapse today. On one hand You suggest we ignore the steep fall in improvement after 9 months and on the other you assure us that Fosun are happy with the data? It takes a certain sort of narcissistic tendency in owns own investment choices , or maybe just outright reckless abandonment if you choose to discount data you don't like and invent approval from others that you have no way of validating.. Kingpin. That is a very nice share price ride, well done! However,please understand me, i was asked what reason/s do i see the share price falling. My posts have generally been about the impact of that data on the share price going forward until the next data rather than predicting the success or failure long term of the treatment!
lauders: What a disappointing day so far! Could get worse too if the US decides to take it lower when they open. Of course US based investors might see a long term opportunity and help the share price rise into the close. Will have to see. Note that someone on LSE called it spot on (so far) before the market opened with a prediction of 50% down on the contents of the RNS. Pretty accurate and the only one to make such a call. Others were mostly calling it up. All we need now, apart from a positive impact from the US open, is a deal like the China one to be announced for another territory. The share price would shoot up again!
bigspuds: By Mark RobinsonWe haven't covered ReNeuron's(RENE) results since the end of 2016, but given the share price has risen by 148 per cent over the past 12 months, an assessment of recent events is in order. In February, the company announced "strongly positive preliminary efficacy data" in relation to clinical trials for its hRPC (human retinal progenitor cells) stem-cell therapy candidate in retinitis pigmentosa, a rare degenerative condition involving a breakdown and loss of cells in the retina.RENE:LSEReNeuron Group PLC1mthToday change-11.82%Price (GBP)242.50All three patients in the study showed "a rapid improvement in vision compared with their pre-treatment baseline". In practical terms, it meant the patients could read an additional four lines of letters on the standard ETDRS (early treatment diabetic retinopathy study) eye chart. Results for all the patients will be presented at the American Academy of Ophthalmology annual meeting in October. Management notes that "an improvement of at least 15 letters from baseline is considered to be clinically meaningful by the US Food and Drug Administration".RENEURON (RENE)   ORD PRICE:248pMARKET VALUE:£79mTOUCH:245-250p12-MONTH HIGH:333pLOW: 48pDIVIDEND YIELD:nilPE RATIO:naNET ASSET VALUE:74pNET DEBT:£26.4mYear to 31 MarTurnover (£000)Pre-tax profit (£m)Earnings per share (p)Dividend per share (p)2015 †30.0-10.3-50.0nil2016 †29.0-12.8-40.0nil2017 †46.0-18.2-49.2nil201843.0-21.0-55.7nil201949.0-17.2-45.2nil% change+14---Ex-div:-   Payment:-   †EPS for 2015-2017 adjusted to take account of capital reorganisationIC ViewReNeuron also commenced patient dosing in the US placebo-controlled Phase IIb clinical trial of its CTX stem-cell therapy candidate in chronic stroke disability, with top-line data from the study due in late 2020. The clinical progress hasn't gone unnoticed. Chinese drugs heavyweight Fosun Pharma has agreed to license the hRPC and CTX therapies as part of a deal worth up to £80m. Financials are of secondary importance as ReNeuron progresses its clinical programme, although N+1 Singer anticipates that cash will run out by March 2022, so it's probable that the gene therapy specialist will be tapping markets at some point.
lauders: Https:// Making sense of 52 week highs 52 week highs are always good news. But you might be surprised to know that the prices of high performing shares can be slow to move when these companies publish positive earnings news. Studies show it happens because investors are wary about bidding high performing shares any higher (even if they deserve it). This unusual behaviour is down to what the psychologists Amos Tversky and Daniel Kahneman called anchoring-and-adjustment. We form beliefs by using reference points (like share prices). But as new information comes to light (like earnings reports) we're often slow to update our beliefs away from the original anchor point. Evidence shows this tug-of-war usually ends with the ‘new high’ stock actually drifting higher in price over the coming weeks and months. The upward trend is called “post earnings announcement drift”. As the news sinks in, momentum takes over and the price moves higher. A look at Reneuron’s StockReport could offer more insight into what’s driving the momentum in its share price - and whether that might continue. If there is some positive media over the weekend the momentum may continue next week, if not there could be a slight pull back for a few days until people start to "speculate" on the details that could be shared on 26th April: Further read-outs from the patients treated in the Phase 1/2 study will be presented at the 6th Annual Retinal Cell and Gene Therapy Innovation Summit, taking place in Vancouver, Canada, on 26 April 2019. Information regarding this conference may be found at: Https:// Also good to see that RENE are being very active when it comes to conferences/events and will be in Kyoto at this event per the website (link below): Https:// Http://
Reneuron share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200803 15:24:17